The immune cell transcriptome is modulated by vitamin D supplementation in people with a first demyelinating event participating in a randomized placebo-controlled trial.
Journal: Clinical immunology (Orlando, Fla.)
Volume: 262
Issue:
Year of Publication:
Affiliated Institutions:
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia; Department of Neurology, Alfred Health, Melbourne, Victoria, Australia. Electronic address: wei.yeh@monash.edu.
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia; Department of Neurology, Alfred Health, Melbourne, Victoria, Australia.
School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, Australia; Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.
Royal Hobart Hospital, Department of Neurology, Hobart, Australia; University of Tasmania, Menzies Institute for Medical Research, Hobart, Australia.
Australian National University, National Centre for Epidemiology and Population Health, Canberra, Australia.
The Florey Institute of Neuroscience and Mental Health, Early Brain Division, Parkville, Australia; University of Melbourne, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia.
Christchurch Hospital, Christchurch, New Zealand; New Zealand Brain Research Institute, Christchurch, New Zealand.
Neuroscience Trials Australia, Heidelberg, Australia.
MS Australia, North Sydney, Australia.
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia; Department of Neurology, Alfred Health, Melbourne, Victoria, Australia; MSBase Foundation, Melbourne, Australia. Electronic address: helmut.butzkueven@monash.edu.
Abstract summary
Vitamin D deficiency is a risk factor for developing multiple sclerosis. The PrevANZ trial was conducted to determine if vitamin D supplementation can prevent recurrent disease activity in people with a first demyelinating event. As a sub-study of this trial, we investigated the effect of supplementation on peripheral immune cell gene expression. Participants were randomized to 1000, 5000 or 10,000 international units daily of vitamin D or placebo. Peripheral blood was collected at baseline and 12 weeks and sent for ribonucleic acid sequencing. Datasets from 55 participants were included. Gene expression was modulated by high dose supplementation. Antigen presentation and viral response pathways were upregulated. Oxidative phosphorylation and immune signaling pathways, including tumor necrosis factor-alpha and interleukin-17 signaling, were downregulated. Overall, vitamin D supplementation for 12 weeks modulated the peripheral immune cell transcriptome with induction of anti-inflammatory gene expression profiles. Our results support a dose-dependent effect of vitamin D supplementation on immune gene expression.
Authors & Co-authors:
Yeh
Gresle
Lea
Taylor
Lucas
Ponsonby
Mason
Andrew
Campbell
Morahan
Sampangi
Campagna
Stankovich
Van der Walt
Jokubaitis
Butzkueven
Study Outcome
Source Link: Visit source